Liquidia Co. (NASDAQ:LQDA) Receives $25.38 Consensus Price Target from Analysts

Shares of Liquidia Co. (NASDAQ:LQDA) have received an average rating of “Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $25.38.

LQDA has been the subject of several research reports. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of Liquidia in a research report on Thursday, January 9th.

Insider Activity

In other news, CEO Roger Jeffs sold 22,343 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at approximately $12,005,905.06. This represents a 2.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the sale, the insider now directly owns 270,388 shares of the company’s stock, valued at $3,185,170.64. The trade was a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 in the last ninety days. 30.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its holdings in Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after purchasing an additional 123,402 shares in the last quarter. Barclays PLC raised its holdings in Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after purchasing an additional 72,591 shares in the last quarter. Whitefort Capital Management LP raised its holdings in Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after purchasing an additional 927,546 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Liquidia by 855.3% during the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after purchasing an additional 210,753 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Trading Up 2.2 %

Shares of LQDA opened at $15.19 on Friday. The firm has a market cap of $1.29 billion, a P/E ratio of -9.32 and a beta of 0.27. The company’s 50-day moving average price is $14.02 and its 200 day moving average price is $11.75. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).